UASt regulatory sequences drive expression of a G298S mutant of Hsap\TARDBP with a C-terminal YFP tag.
eye, with Scer\GAL4GMR.PU
eye | adult stage, with Scer\GAL4GMR.PU
Overexpression of Hsap\TARDBPG298S.Scer\UAS.T:Avic\GFP-YFP driven in motor neurons by Scer\GAL4Toll-6-D42 in larvae results in locomotor dysfunction (significant increase in the amount of time taken for the larva to turn from dorsal side and resume crawling on the ventral side).
Ectopic expression of Hsap\TARDBPG298S.Scer\UAS.T:Avic\GFP-YFP under the control of Scer\GAL4GMR.PU results in an age-dependent depigmentation phenotype in the adult eye indicative of neurodegeneration.
Ectopic expression of Hsap\TARDBPG298S.Scer\UAS.T:Avic\GFP-YFP under the Scer\GAL4Toll-6-D42 driver significantly lengthens the time it takes for larvae to roll over in a turning assay and reduces adult life span compared to wild-type.
Ectopic expression of Hsap\TARDBPG298S.Scer\UAS.T:Avic\GFP-YFP under the control of Scer\GAL4Toll-6-D42 results in significantly increased number of satellite boutons and significantly decreased density of futsch positive loops on synaptic boutons on neuromuscular junctions of third instar larvae compared to wild-type controls.
Expression of Hsap\TARDBPG298S.Scer\UAS.T:Avic\GFP-YFP in motor neurons under the control of Scer\GAL4D42 is lethal at the pupal or pharate adult stage. Few pharate adults eclose but cannot extend their wings. Larvae expressing Hsap\TARDBPScer\UAS.T:Avic\GFP-YFP.cEa display locomotor dysfunction in turning assays. Treatment with pioglitazone results in improved larval locomotor function and the survival of the animals to adulthood. However, pioglitazone-treatment is not effective at improving the lifespan of the transgenic adults.
Expression of Hsap\TARDBPG298S.Scer\UAS.T:Avic\GFP-YFP in glia under the control of Scer\GAL4repo causes locomotor function abnormalities. Pioglitazone-treatment mitigates the locomotor dysfunction phenotype. However, pioglitazone-treatment is not effective at improving the lifespan of the transgenic adults expressing Hsap\TARDBPG298S.Scer\UAS.T:Avic\GFP-YFP in glia.
Muscle-specific expression of Hsap\TARDBPG298S.Scer\UAS.T:Avic\GFP-YFP using Scer\GAL4BG487 results in larval locomotor defects which is not mitigated by pioglitazone-treatment.
This expression results in a decreased adult lifespan compared to controls.
Expression of Scer\GAL4GMR.PU>Hsap\TARDBPG298S.Scer\UAS.T:Avic\GFP-YFP leads to age- and dose-dependent neurodegeneration as indicated by depigmentation in the eye.
Expression of Hsap\TARDBPG298S.Scer\UAS.T:Avic\GFP-YFP in motor neurons under the control of Scer\GAL4D42 results in nuclear morphology defects and smaller synapses compared with wild-type. This anatomical phenotype is accompanied by an impairment in locomotor function, as indicated by a significant increase in larval turning time compared with controls.
Compared with controls, expression of Hsap\TARDBPG298S.Scer\UAS.T:Avic\GFP-YFP in glial cells under the control of Scer\GAL4repo.PU results in significantly smaller neuromuscular junctions (NMJs) with a decreased number of synaptic boutons. When tested for their ability to turn, larvae expressing the transgene in glia also exhibit a significant impairment in locomotor function.
Hsap\TARDBPG298S.Scer\UAS.T:Avic\GFP-YFP-expression leads to a mismatch of pre- and post-synaptic areas. Expression of Hsap\TARDBPG298S.Scer\UAS.T:Avic\GFP-YFP in motor neurons leads to a significant increase in the area of pre-synaptic active zones, while its expression in glia results in reduction in the size of post-synaptic areas.
Both motor neuron and glial expression of Hsap\TARDBPG298S.Scer\UAS.T:Avic\GFP-YFP can lead to alterations in adult locomotion and sleep patterns.
Hsap\TARDBPG298S.UAS.YFP, Scer\GAL4Toll-6-D42 has abnormal locomotor behavior | larval stage phenotype, enhanceable by Pabp255
Hsap\TARDBPG298S.UAS.YFP, Scer\GAL4GMR.PU has abnormal eye color | adult stage phenotype, enhanceable by Fmr1GD1288, Scer\GAL4GMR.PU
Hsap\TARDBPG298S.UAS.YFP, Scer\GAL4GMR.PU has abnormal eye color | adult stage phenotype, enhanceable by Fmr1Δ50M/Fmr1[+]
Hsap\TARDBPG298S.UAS.YFP, Scer\GAL4Toll-6-D42 has abnormal locomotor behavior | third instar larval stage phenotype, enhanceable by Fmr1GD1288, Scer\GAL4Toll-6-D42
Hsap\TARDBPG298S.UAS.YFP, Scer\GAL4Toll-6-D42 has abnormal locomotor behavior | third instar larval stage phenotype, enhanceable by Fmr1Δ50M/Fmr1[+]
Hsap\TARDBPG298S.UAS.YFP, Scer\GAL4Toll-6-D42 has abnormal neuroanatomy | third instar larval stage phenotype, suppressible by Fmr1UAS.YFP, Scer\GAL4Toll-6-D42
Hsap\TARDBPG298S.UAS.YFP, Scer\GAL4GMR.PU has abnormal eye color | adult stage phenotype, suppressible by Fmr1UAS.YFP, Scer\GAL4GMR.PU
Hsap\TARDBPG298S.UAS.YFP, Scer\GAL4Toll-6-D42 has abnormal locomotor behavior | third instar larval stage phenotype, suppressible by Fmr1UAS.YFP, Scer\GAL4Toll-6-D42
Hsap\TARDBPG298S.UAS.YFP, Scer\GAL4Toll-6-D42 has short lived phenotype, suppressible by Fmr1UAS.YFP, Scer\GAL4Toll-6-D42
Hsap\TARDBPG298S.UAS.YFP, Scer\GAL4Toll-6-D42 has abnormal locomotor behavior | larval stage phenotype, suppressible by futschEP1419, Scer\GAL4Toll-6-D42
Hsap\TARDBPG298S.UAS.YFP, Scer\GAL4Toll-6-D42 has short lived phenotype, suppressible by futschEP1419, Scer\GAL4Toll-6-D42
Hsap\TARDBPG298S.UAS.YFP, Scer\GAL4Toll-6-D42 has abnormal neuroanatomy phenotype, suppressible by futschEP1419, Scer\GAL4Toll-6-D42
Hsap\TARDBPG298S.UAS.YFP, Scer\GAL4Toll-6-D42 has abnormal locomotor behavior | larval stage phenotype, non-suppressible by futschHMS02000, Scer\GAL4Toll-6-D42
Eip75BΔ51/Eip75B[+], Hsap\TARDBPG298S.UAS.YFP, Scer\GAL4Toll-6-D42 has abnormal locomotor behavior | third instar larval stage phenotype
Hsap\TARDBPG298S.UAS.YFP, Scer\GAL4GMR.PU has eye | adult stage phenotype, enhanceable by Fmr1GD1288, Scer\GAL4GMR.PU
Hsap\TARDBPG298S.UAS.YFP, Scer\GAL4GMR.PU has eye | adult stage phenotype, enhanceable by Fmr1Δ50M/Fmr1[+]
Hsap\TARDBPG298S.UAS.YFP, Scer\GAL4GMR.PU has eye | adult stage phenotype, suppressible by Fmr1UAS.YFP, Scer\GAL4GMR.PU
Hsap\TARDBPG298S.UAS.YFP, Scer\GAL4Toll-6-D42 has NMJ bouton | third instar larval stage phenotype, suppressible by Fmr1UAS.YFP, Scer\GAL4Toll-6-D42
Hsap\TARDBPG298S.UAS.YFP, Scer\GAL4Toll-6-D42 has NMJ bouton phenotype, suppressible by futschEP1419, Scer\GAL4Toll-6-D42
Pabp255 significantly enhances locomotor dysfunction seen in larvae with expression of Hsap\TARDBPG298S.Scer\UAS.T:Avic\GFP-YFP driven by Scer\GAL4GMR.PU.
The depigmentation phenotype in the adult eye and the lengthened time it takes for larvae to roll over in a turning assay characteristic for animals expressing Hsap\TARDBPG298S.Scer\UAS.T:Avic\GFP-YFP under the control of Scer\GAL4GMR.PU or Scer\GAL4Toll-6-D42 respectively, are exacerbated further by co-expression of Fmr1GD1288 RNAi. However, co-expression of Hsap\TARDBPG298S.Scer\UAS.T:Avic\GFP-YFP and Fmr1GD1288 under the Scer\GAL4Toll-6-D42 driver is pupal stage lethal.
The depigmentation phenotype in the adult eye and the lengthened time it takes for larvae to roll over in a turning assay characteristic for animals expressing Hsap\TARDBPG298S.Scer\UAS.T:Avic\GFP-YFP under the control of Scer\GAL4GMR.PU or Scer\GAL4Toll-6-D42 respectively, are restored by co-expression of Fmr1Scer\UAS.T:Avic\GFP-YFP.
The short adult life span, the increased number of satellite boutons along with the reduction in the density of futsch positive loops on synaptic boutons on neuromuscular junctions of third instar larvae characteristic for animals expressing Hsap\TARDBPG298S.Scer\UAS.T:Avic\GFP-YFP under the control of Scer\GAL4Toll-6-D42 can be fully (satellite boutons) or partially (loops density on synaptic boutons, adult life span) rescued by co-expression of Fmr1Scer\UAS.T:Avic\GFP-YFP.
The depigmentation phenotype in the adult eye and the lengthened time it takes for larvae to roll over in a turning assay characteristic for animals expressing Hsap\TARDBPG298S.Scer\UAS.T:Avic\GFP-YFP under the control of Scer\GAL4GMR.PU or Scer\GAL4Toll-6-D42 respectively, are exacerbated further by combination with Fmr1Δ50M in heterozygous state.
Pioglitazone can no longer rescue the Scer\GAL4D42>Hsap\TARDBPG298S.Scer\UAS.T:Avic\GFP-YFP-dependent larval turning defects in a heterozygous Eip75BΔ51 genetic background.
Pioglitazone can no longer rescue the Scer\GAL4D42>Hsap\TARDBPG298S.Scer\UAS.T:Avic\GFP-YFP-dependent larval turning defects when Eip78CJF02258 is co-expressed.
Expression of futschHMS02000 does not suppress the larval turning phenotype seen when Hsap\TARDBPG298S.Scer\UAS.T:Avic\GFP-YFP is expressed under the control of Scer\GAL4D42, but the flies are lethal at the pupal stage.
Expression of futschEP1419 partially suppresses the larval turning and reduced lifespan phenotypes seen when Hsap\TARDBPG298S.Scer\UAS.T:Avic\GFP-YFP is expressed under the control of Scer\GAL4D42.
Expression of futschEP1419 fully suppresses the reduction in boutons compared with controls seen when Hsap\TARDBPG298S.Scer\UAS.T:Avic\GFP-YFP is expressed under the control of Scer\GAL4D42. The increase in satellite bouton number in the larval NMJ is suppressed to control levels.